

# Biologics Market to record USD 567.96 Bn growth, Evolving Opportunities with ILYA Pharma, Elasmogen and TiumBio

*Rising occurrences of target conditions and advancements in biomedical technology are among the significant factors influencing market revenue growth*

VANCOUVER, BC, CANADA, September 22, 2022 /EINPresswire.com/ -- The global [biologics market](#) is projected to reach USD 567.96 Billion in 2028 at a steady revenue CAGR of 8.4% over the forecast period, according to latest analysis by Emergen Research. Some key factors attributed to steady market

revenue growth include rising demand for monoclonal antibodies, recombinant hormones/proteins, gene-based & cellular-based biologics, vaccines, and molecular therapy, etc. in the treatment of diseases including cancer, infectious diseases, immunological diseases, cardiovascular diseases, and hematological diseases, among others. Also, rising use of biologics

for the treatment of autoimmune diseases, comprising various arthritis types, including ankylosing spondylitis, rheumatoid arthritis, and psoriatic arthritis, is playing a crucial role in driving revenue growth of the global biologics market. Biologics function by creating an inflammation disruption, thereby resulting in a reduction in joint pain.

Surging demand and higher adoption of novel biologics drugs and therapies across the globe for the treatment of disease conditions is a significant factor causative of

“

Biologics Market Size – USD 299.72 Billion in 2020, Market Growth - CAGR of 8.4%, Market Trends –Surging demand and higher adoption of novel therapies”

*Emergen Research*



steady market revenue growth. One such novel drug is Antibody-Drug Conjugate (ADC), which is a highly effective drug used in disease treatment. In cancer treatment, ADC delivers drugs to the disease/target cells with a very high specificity, thereby maximizing efficacy and lessening

systemic exposure, as well as associated side effect risks. Based on payload attached to the antibody, ADC can be deployed to influence several biological functions.

□□□□□□ □□ □□□□□□□□ □□□□□□ □□ □□□□ □□□□□□□□□□ □□□□□□ :-

<https://www.emergenresearch.com/request-sample/61>

It offers detailed insights into the impact of COVID-19 on the industry at a regional level and industry level. The report also covers the developments and government regulations related to COVID-19. The report further analyzes the current and future impact of COVID-19 on the global market and provides an insight into the post-COVID-19 situation.

□□□□ □□□ □□□□□□□□□□□□ □□□□ □□□ □□□□□□□ □ :

In September 2020, Biocon Biologics Ltd. and Mylan made an announcement about the introduction of biosimilar Semglee in the US. This biosimilar is available, both in pre-filled pen and vials, and is intended for controlling high blood pressure in adults having type 2 diabetes and pediatric patients having type 1 diabetes.

Among the source segments, mammalian segment revenue is expected to register a significantly rapid growth rate over forecast period. Expression systems deploying mammalian cells for recombinant hormones/proteins can introduce appropriate protein folding, PTM (post-translational modifications), and product assembly that are essential for overall biological activity.

Among the product type segments, vaccines segment revenue is expected to expand at a relatively faster rate over forecast period. A vaccine functions by preparing the immune system to identify and fight pathogens, either bacteria or viruses. Vaccines are beneficial in reducing preventable infectious diseases, and currently, fewer number individuals suffer from the distressing effects of pertussis and measles, among other illnesses. Presently, vaccines are witnessing spiraling demand across the globe to curb the spread of COVID-19 and resulting mortalities occurring due to the disease.

Among the application segments, the cancer segment accounted for largest revenue share in 2020. Biologics assists the immune system in quickly recognizing cancer cells in the human body, as well as attacking the malignant cells, switching on/off the signals from cancerous cells and aiding in dodging the immune system cells.

□□□ □□□□□□□□□□ □□□□□□□□ □□ □□□ □□□□□□□□□□ □□□□□□ □□□□□□□□ : Novo Nordisk A/S, Pfizer Inc., Amgen, Sanofi, Samsung BioLogics, Merck & Co. Inc., Celltrion, AbbVie Inc., Johnson & Johnson Services Inc., Eli Lilly & Company, F Hoffman La Roche, Addgene, Novartis AG, and GlaxoSmithKline.

□□□□ □□□□ □□□□□□□□ □□ □□□ □□□□□□□□□□ □□□□ □□□ □□□□□□□□□□ □□□□□□ @

<https://www.emergenresearch.com/industry-report/biologics-market>

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study.

□□□□□□ □□□□□□□□ □□ □□□□□□□□ □□ □□□□□ □□□□□□□□ □□ □□ □□□□ □□ □□□□□□, □□□□□□ □□□□, □□□□□□□□□□□□, □□□ □□□□□□□:

□□□□□□ □□□□□□ (□□□□□□□□, □□□ □□□□□□□□; □□□□□-□□□□□)

Microbial

Mammalian

Others

□□□□□□□□ □□□□ □□□□□□□□ (□□□□□□□□, □□□ □□□□□□□□; □□□□□-□□□□□)

Monoclonal Antibodies

Vaccines

Recombinant Hormones/Proteins

Cellular-Based Biologics

Gene-Based Biologics

Others

□□□□□□□□□□□□ □□□□□□□□ (□□□□□□□□, □□□ □□□□□□□□; □□□□□-□□□□□)

Cancer

Infectious Diseases

Immunological Diseases

Cardiovascular Diseases

Hematological Disorders

Others

□□□□□□□□ □□□ □□□□□□□□□□□□□□□ □□□□□□□□□□ □□□□□□ □□□□□□ □□□□□□ @

<https://www.emergenresearch.com/request-for-customization/61>

□□□□□□□□ □□□□□□□□□:

The global Biologics Market has been categorized on the basis of key geographical regions into North America, Asia Pacific, Europe, Latin America, and Middle East & Africa. It evaluates the presence of the global Biologics Market in the major regions with regards to market share, market size, revenue contribution, sales network and distribution channel, and other key elements

□□□□□□□□ □□□□□□ □□□□ @ <https://www.emergenresearch.com/request-sample/61>

